相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
Erika Martinelli et al.
CLINICAL CANCER RESEARCH (2010)
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2008)
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
Ignacio Duran et al.
CLINICAL CANCER RESEARCH (2007)
Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer
Cesare Gridelli et al.
ONCOLOGIST (2007)
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
JR Tonra et al.
CLINICAL CANCER RESEARCH (2006)
Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel
C Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
DG Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)